https://www.einpresswire.com/article/622987599/bimekizumab-phase-3-data-in-hidradenitis-suppurativa-show-clinically-meaningful-deep-and-maintained-response-over-48-weeks
Patients treated with investigational bimekizumab, an IL-17A and IL-17F inhibitor, achieved statistically significant and clinically meaningful improvements
hidradenitis suppurativabimekizumabphasedatashow
https://www.ajmc.com/view/bimekizumab-poised-to-tackle-unmet-hs-treatment-needs
Hidradenitis suppurativa (HS) is an inflammatory, chronic disease with very high symptom and physical burdens, and it can get progressively worse over time if...
bimekizumabpoisedtackleunmeths